WO2016048005A3 - 신규한 펜타디에노일 피페리딘 유도체 및 그의 용도 - Google Patents

신규한 펜타디에노일 피페리딘 유도체 및 그의 용도 Download PDF

Info

Publication number
WO2016048005A3
WO2016048005A3 PCT/KR2015/009944 KR2015009944W WO2016048005A3 WO 2016048005 A3 WO2016048005 A3 WO 2016048005A3 KR 2015009944 W KR2015009944 W KR 2015009944W WO 2016048005 A3 WO2016048005 A3 WO 2016048005A3
Authority
WO
WIPO (PCT)
Prior art keywords
piperidine derivative
metabolic disease
novel
blood
pentadienoyl
Prior art date
Application number
PCT/KR2015/009944
Other languages
English (en)
French (fr)
Other versions
WO2016048005A2 (ko
Inventor
박태선
정낙신
Original Assignee
연세대학교 산학협력단
서울대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단, 서울대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to US15/513,072 priority Critical patent/US10100011B2/en
Publication of WO2016048005A2 publication Critical patent/WO2016048005A2/ko
Publication of WO2016048005A3 publication Critical patent/WO2016048005A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 신규한 펜타디에노일 피페리딘 유도체, 이를 포함하는 대사질환의 예방 또는 치료용 약제학적 조성물 및 이를 이용한 대사질환의 개선 또는 완화용 기능성 식품 조성물에 관한 것이다. 본 발명의 펜타디에노일 피페리딘 유도체는 지방전구세포의 분화를 억제하며, 체중 및 내장지방을 감소시키고, 혈중 지질농도를 감소시키며, 혈중 간기능지표를 개선시키고, 혈당을 감소시킬 뿐 아니라 대사성염증반응을 억제함으로써 궁극적으로 비만, 당뇨, 이상지방혈증, 지방간 및 인슐린 저항성 증후군으로 구성된 군으로부터 선택되는 대사질환의 예방 또는 치료 활성을 나타내는 의약 또는 기능성 식품 조성물로서 유용하게 이용될 수 있다.
PCT/KR2015/009944 2014-09-23 2015-09-22 신규한 펜타디에노일 피페리딘 유도체 및 그의 용도 WO2016048005A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/513,072 US10100011B2 (en) 2014-09-23 2015-09-22 Pentadienoyl piperidine derivative and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140126959A KR101498218B1 (ko) 2014-09-23 2014-09-23 신규한 펜타디에노일 피페리딘 유도체 및 그의 용도
KR10-2014-0126959 2014-09-23

Publications (2)

Publication Number Publication Date
WO2016048005A2 WO2016048005A2 (ko) 2016-03-31
WO2016048005A3 true WO2016048005A3 (ko) 2016-08-18

Family

ID=53026106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/009944 WO2016048005A2 (ko) 2014-09-23 2015-09-22 신규한 펜타디에노일 피페리딘 유도체 및 그의 용도

Country Status (3)

Country Link
US (1) US10100011B2 (ko)
KR (1) KR101498218B1 (ko)
WO (1) WO2016048005A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101844184B1 (ko) * 2017-07-21 2018-04-02 씨제이헬스케어 주식회사 아미노알킬벤조티아제핀 유도체의 용도
KR102005423B1 (ko) * 2017-10-31 2019-07-30 주식회사 휴엔 단삼 추출물을 함유하는 내장지방형 비만 예방, 개선 또는 치료 조성물
EP3778571A1 (en) 2018-03-27 2021-02-17 Bioway, Inc. (2e,4e)-5-phenyl-penta-2,4-dien-1-one derivative
WO2019207553A2 (en) * 2018-04-27 2019-10-31 Joslin Diabetes Center, Inc. Methods and compositions relating to lipokines for treating metabolic disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121994A1 (en) * 2002-12-20 2004-06-24 Anderson Steven N. Novel amides that activate soluble guanylate cyclase
WO2005019177A1 (en) * 2003-08-14 2005-03-03 Icos Corporation Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
WO2006068075A1 (ja) * 2004-12-21 2006-06-29 Kaneka Corporation ペルオキシソーム増殖剤応答性受容体γリガンド剤
US20070142394A1 (en) * 2005-12-21 2007-06-21 Schering Corporation Substituted aniline derivatives useful as histamine H3 antagonists
WO2009004071A1 (en) * 2007-07-03 2009-01-08 Sygnis Bioscience Gmbh & Co. Kg Use of piperine and derivatives thereof for the therapy of neurological conditions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121994A1 (en) * 2002-12-20 2004-06-24 Anderson Steven N. Novel amides that activate soluble guanylate cyclase
WO2005019177A1 (en) * 2003-08-14 2005-03-03 Icos Corporation Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
WO2006068075A1 (ja) * 2004-12-21 2006-06-29 Kaneka Corporation ペルオキシソーム増殖剤応答性受容体γリガンド剤
US20070142394A1 (en) * 2005-12-21 2007-06-21 Schering Corporation Substituted aniline derivatives useful as histamine H3 antagonists
WO2009004071A1 (en) * 2007-07-03 2009-01-08 Sygnis Bioscience Gmbh & Co. Kg Use of piperine and derivatives thereof for the therapy of neurological conditions

Also Published As

Publication number Publication date
WO2016048005A2 (ko) 2016-03-31
US10100011B2 (en) 2018-10-16
KR101498218B1 (ko) 2015-03-12
US20170320825A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
PH12020500169A1 (en) Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
WO2019066577A3 (ko) 짧은 사슬 지방산 생성 장내 세균 군집의 변화를 이용한 알코올성 간 질환의 진단 및 치료용 조성물
RU2014112223A (ru) Способ профилактики и/или лечения инсулинорезистентности
WO2016048005A3 (ko) 신규한 펜타디에노일 피페리딘 유도체 및 그의 용도
WO2016042163A3 (en) Ophthalmic drug compositions
MX355065B (es) Método y dispositivo para conmutación de cámaras.
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
WO2010030054A3 (en) Uses of sesquiterpene derivatives
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
WO2014058979A8 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
PH12015502263B1 (en) Composition for preventing or treating hangover
IN2014DN08240A (ko)
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
WO2016068453A8 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
EP3456337A4 (en) PHARMACEUTICAL COMPOSITION AND FUNCTIONAL HEALTH FOOD COMPRISING AVENANTHRAMIDE C OAT EXTRACT OR DERIVATIVE THEREOF AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE
WO2013025073A3 (ko) 유홍초 추출물을 함유하는 당뇨합병증 예방 또는 치료용 조성물
PH12017500795A1 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
WO2016190566A3 (ko) 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품
WO2015121457A8 (en) Fgf-8 for use in treating diseases or disorders of energy homeostasis
WO2016085321A3 (en) Composition comprising a pentose and polyphenolic compound
WO2019022482A3 (ko) 황칠나무 추출물을 유효성분으로 포함하는 섬유화 질환의 예방 또는 치료용 조성물
WO2013085338A3 (ko) 수련뿌리 추출물, 이의 분획물 또는 이로부터 분리된 폴리페놀계 화합물을 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물
WO2016008642A3 (en) Compositions comprising cinnamaldehyde and zinc and methods of using such compositions
WO2012105816A3 (ko) 새콩 분말 또는 이의 추출물을 포함하는 당뇨병 및 당뇨합병증 예방 및 치료를 위한 조성물
WO2011090265A3 (ko) 신코닌을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15843665

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15513072

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15843665

Country of ref document: EP

Kind code of ref document: A2